An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer

Ribosomal S6 kinase has been shown to play a key role in cellular resistance to endocrine therapy in prostate cancer through its regulation of YB‐1/androgen receptor (AR) signaling. PMD‐026, an oral first‐in‐class small molecule kinase inhibitor, is the first identified ribosomal S6 kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ushijima, Miho, Shiota, Masaki, Matsumoto, Takashi, Kashiwagi, Eiji, Inokuchi, Junichi, Eto, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128173/
https://www.ncbi.nlm.nih.gov/pubmed/35118769
http://dx.doi.org/10.1111/cas.15280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128173/
https://www.ncbi.nlm.nih.gov/pubmed/35118769
http://dx.doi.org/10.1111/cas.15280

Ejemplares similares